Acute cellular rejection (ACR) after orthotopic liver transplantation occurs in 50% to 80% of
patients despite the recent advances in immunosuppressive therapy. Adjuvant use of …

Acute rejection following orthotopic liver transplantation is a common problem despite
current immunosuppressive regimens. Ursodeoxycholic acid (UDCA) has been shown in …

Steroid-resistant rejection continues to be a serious problem in liver transplantation. Since
ursodeoxycholic acid (UDCA) is beneficial in several cholestatic disorders and possesses in …

Background/Aims: Acute rejection is still a major problem after liver transplantation.
Ursodeoxycholic acid has beneficial effects in cholestasis by reducing the expression of …

Background. Prophylactic treatment with ursodeoxycholic acid (UDCA) has been reported to
reduce the incidence of acute rejection after liver transplantation compared with historical …

Acute rejection, occurring with a reported frequency of 50–70%, is still a dominating problem
after liver transplantation. Medication with ursodeoxycholic acid (UDCA) has beneficial …

Background Acute cellular rejection (ACR) after liver transplantation (LT) is one of the most
common problems faced by transplant recipients in spite of advances in immunosuppressive …

Background. Total immunosuppression withdrawal (TIW) without causing rejection has been
reported in stable liver recipients. The role of ursodeoxycholic acid (UDCA) and patient …

There are many different causes of graft dysfunction and cholestasis after liver
transplantation. These include non-primary function, preservation and reperfusion injury …

As ursodeoxycholic acid (UDCA) delays the need for transplantation, this could result in
patients with more comorbid disease, therefore more likely to have a worse outcome …